Advent International’s Aegerion Pharmaceuticals AEGR Stock Holding History

Advent International’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-198,001	Closed	-$3.76M	–	16
2015 Q2	$3.76M	Sell	198,001 -149,000	-43%	-$3.22M	0.09%	5
2015 Q1	$9.08M	Sell	347,001 -25,000	-7%	-$636K	0.7%	2
2014 Q4	$7.79M	Sell	372,001 -75,000	-17%	-$1.89M	6.22%	2
2014 Q3	$14.9M	Hold	447,001	–	–	1.74%	2
2014 Q2	$14.3M	Sell	447,001 -50,000	-10%	-$1.86M	100%	1
2014 Q1	$23M	Sell	497,001 -50,000	-9%	-$2.93M	10.47%	2
2013 Q4	$38.8M	Sell	547,001 -158,299	-22%	-$12.1M	4.56%	3
2013 Q3	$60.5M	Sell	705,300 -172,500	-20%	-$14.6M	5.01%	3
2013 Q2	$55.6M	Buy	+877,800	New	+$46.6M	2.72%	3

Other funds holding AEGR

ACM

Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Advent International's AEGR Position: Q3 2015 in Review

Advent International sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2015, closing a stake of 198,001 shares — an estimated $3.76M sold.

Advent International first reported a position in AEGR in Q2 2013 and held it in 9 quarters. The position peaked at $60.5M in Q3 2013. 96 funds tracked by Wall St. Rank hold AEGR as of Q3 2015.

Advent International reported no remaining Aegerion Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Advent International sold 198,001 Aegerion Pharmaceuticals shares in Q3 2015, an estimated $3.76M.
Advent International first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 9 quarters.
Advent International's Aegerion Pharmaceuticals position peaked at $60.5M in Q3 2013.
96 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2015.

Based on Advent International's 13F filing for Q3 2015, filed 20 Oct 2015.